Document QM4q20Em8L1kZEKeVVdorQq68

F.l Cases of Severe AA, MDS, AML, BID or BP Cases Subjects will be recruited to the study by hospital Clinical Coordinators on the basis of initial clinical presentation, clinical history and/or previous preliminary blood work. Interviewers will obtain informed consent, administer study questionnaire and schedule blood draw and bone marrow biopsy-aspiration procedure with coordinator, hospital and laboratory Collection Team. In addition, interviewers will provide Exposure Assessment Team with the subject's questionnaire information pertinent to identity, employment and exposure history. BP cases identified in the companion Molecular Epidemiology study will be admitted to a participating hospital, subjected to full benzene exposure assessment and assigned a control. F.3 Outside cases of Benzene-induced AA, MDS or AML A small number of cases of benzene-induced disease referred by physicians outside Shanghai will be recruited as cases. Criteria will include defmitive (quantitative or anecdotal) evidence of previous benzene exposure and a diagnosis of BP. These cases will be subject to full benzene exposure analysis but will not be assigned hospital controls. Depending on individual circumstances, patients will be evaluated either in Shanghai or in their city or province of residence. G Follow-up The presenting clinical and molecular characteristics of individual cases of BP, AA, MDS and AML will be characterized and recorded in the study database. Cases of BP, AA and MDS also will be re-evaluated at regular 6 month follow-up periods through June, 2007. Results will be compared in order to evaluate the clinical and molecular progression of these diseases and will be reported to treating physicians. Cases of AML will not be subject to routine follow-up as part of this study but will be followed in support of clinical management at the request of the treating physician. 3 PROJECT MILESTONES AND DELIVERABLES 3.1 Deliverables Case Control and Disease Progression Studies Continued laboratory operations and diagnosis of Hematopoietic and Lymphoid Neoplasms (WHO, 2001) for participating hospitals in Shanghai. o AML, MDS, AA, BID, BP through 6/30/07 o BID, BP through 12/31107 o Continued case accrual for DP and diagnostic support through 12/31107 o NHL through 12/31107 24 SH ELL-MCCLU RG-059742